ILT4 facilitates angiogenesis in non‐small cell lung cancer
Cancer Science · 2024-05 · 115 (5) · 1459-1475
DOI: 10.1111/cas.16126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.03.2024. Verfasst von Shuyun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neovascularization, Pathologic, Receptors, Immunologic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jinan Science and Technology Innovation Program of Clinical Medicine, Postdoctoral Innovation Project of Shandong Province, Science and Technology Project of Jinan Health Commission.
Abstract (Originalsprache)
Antiangiogenic therapy targeting VEGF‐A has become the standard of first‐line therapy for non‐small cell lung cancer (NSCLC). However, its clinical response rate is still less than 50%, and most patients eventually develop resistance, even when using combination therapy with chemotherapy. The major cause of resistance is the activation of complex bypass signals that induce angiogenesis and tumor progression. Therefore, exploring novel proangiogenic mechanisms and developing promising targets for combination therapy are crucial for improving the efficacy of antiangiogenic therapy. Immunoglobulin‐like transcript (ILT) 4 is a classic immunosuppressive molecule that inhibits myeloid cell activation. Recent studies have shown that tumor cell‐derived ILT4 drives tumor progression via the induction of malignant biologies and creation of an immunosuppressive microenvironment. However, whether and how ILT4 participates in NSCLC angiogenesis remain elusive. Herein, we found that enriched ILT4 in NSCLC is positively correlated with high microvessel density, advanced disease, and poor overall survival. Tumor cell‐derived ILT4 induced angiogenesis both in vitro and in vivo and tumor progression and metastasis in vivo. Mechanistically, ILT4 was upregulated by its ligand angiopoietin‐like protein 2 (ANGPTL2). Their interaction subsequently activated the ERK1/2 signaling pathway to increase the secretion of the proangiogenic factors VEGF‐A and MMP‐9, which are responsible for NSCLC angiogenesis. Our study explored a novel mechanism for ILT4‐induced tumor progression and provided a potential target for antiangiogenic therapy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Medical Research & Laboratory Diagnostic Center, Central Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Oncology, Yantai Yuhuangding Hospital, Medical College, Qingdao University, Yantai, Shandong, China.
- Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
ORCID-Profile: Yuping Sun
Förderung
- Jinan Science and Technology Innovation Program of Clinical Medicine
- Postdoctoral Innovation Project of Shandong Province
- Science and Technology Project of Jinan Health Commission
- Key R & D Program of Shandong Province
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Wang, J., Gong, W., Zhang, F., Chen, X., Xu, H., Han, Y., Fu, X., Wang, L., Li, J., Gao, A., & Sun, Y. (2024). ILT4 facilitates angiogenesis in non‐small cell lung cancer. Cancer Science, 115(5), 1459-1475. https://doi.org/10.1111/cas.16126
Vancouver
Wang S, Wang J, Gong W, Zhang F, Chen X, Xu H, et al. ILT4 facilitates angiogenesis in non‐small cell lung cancer. Cancer Science. 2024;115(5):1459-1475. doi:10.1111/cas.16126
BibTeX
@article{Wang2024,
author = {Wang, Shuyun and Wang, Jing and Gong, Wenjing and Zhang, Fang and Chen, Xiaozheng and Xu, Huijun and Han, Yali and Fu, Xuebing and Wang, Leirong and Li, Juan and Gao, Aiqin and Sun, Yuping},
title = {ILT4 facilitates angiogenesis in non‐small cell lung cancer},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {5},
pages = {1459--1475},
doi = {10.1111/cas.16126}
}
EUVIMED